Nektar Therapeutics NKTR
37.81 USD -0.63 (-1.64%)
Nov 12, 2026, 2:14 PM EST
37.01 Day range 38.32
33.40 52-week range 109.00
- YTD
- -10.57%
- 1 year
- -34.44%
News
prnewswire.com Nektar Therapeutics to Participate in Two Investor Conferences in November SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS Global…
defenseworld.net CenterBook Partners LP Buys 26,346 Shares of Nektar Therapeutics $NKTR CenterBook Partners LP bought a new position in Nektar Therapeutics (NASDAQ: NKTR) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission.…
benzinga.com UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53 UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.
benzinga.com Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130 Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.
benzinga.com BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
benzinga.com Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating.
benzinga.com HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's regular session. The company's market cap stands at $3.5 million. Stablecoin Development (AMEX:SDEV) stock…
benzinga.com Nektar Therapeutics Presents Data On Rezpegaldesleukin From Its Phase 2b REZOLVE-A, Phase 2b REZOLVE-AD Trials At European Academy Of Dermatology And Venereology Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of…
benzinga.com BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
benzinga.com Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in lawsuit over their rezpegaldesleukin licensing agreement.- benzinga.com BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
- benzinga.com Nektar Therapeutics Announces That Jury Found Lilly Did Breach Implied Covenant Of Good Faith And Fair Dealing Under License Agreement; Company Awarded $90M In Damages Plus Interest On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The jury awarded the Company $90 million…
- benzinga.com Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $50 Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $80 to $50.
benzinga.com BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.- benzinga.com BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
- benzinga.com Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Moderate-To-Severe Atopic Dermatitis REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2wFirst large, placebo-controlled trial to support…
- benzinga.com JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.
benzinga.com Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For…- benzinga.com Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153 Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $153.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029 Two global registrational Phase 3 trials initiated in ZENITH AD programPhase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with…
- benzinga.com Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80 Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $95 to $80.
- benzinga.com Nektar Therapeutics To Offer Up To $150M In Common Stock Via Equity Distribution Agreement On May 8, 2026, Nektar Therapeutics (the "Company") entered into an Equity Distribution Agreement (the "Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and H.C. Wainwright &…
benzinga.com Piper Sandler Maintains Overweight on Nektar Therapeutics, Raises Price Target to $192 Piper Sandler analyst Yasmeen Rahimi maintains Nektar Therapeutics (NASDAQ:NKTR) with a Overweight and raises the price target from $105 to $192.- benzinga.com Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(1.62) by 12.35 percent. This is a 49.72 percent increase over losses…
- benzinga.com Citigroup Maintains Buy on Nektar Therapeutics, Raises Price Target to $151 Citigroup analyst Samantha Semenkow maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $123 to $151.
- benzinga.com Wedbush Maintains Neutral on Nektar Therapeutics, Raises Price Target to $95 Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raises the price target from $70 to $95.
- benzinga.com Nektar Therapeutics Launches $250M Common Stock Offering Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an…
- benzinga.com HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $185 HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $165 to $185.
- benzinga.com BTIG Maintains Buy on Nektar Therapeutics, Raises Price Target to $178 BTIG analyst Julian Harrison maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $151 to $178.
benzinga.com Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.
benzinga.com Why Are Nektar Shares Up Monday? Nektar Therapeutics shares are trading higher Monday after a blinded 16-week treatment extension results in Phase 2b REZOLVE-AA study.
benzinga.com Nektar Therapeutics Announces Its Phase 2b REZOLVE-AA Trial Evaluating Rezpegaldesleukin Demonstrates 29% And 31% Of Participants In Two Different Doses Extension Achieves New Severity Of Alopecia Tool Score Of Less Than Or Equal To 20 Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced new results from a blinded 16-week treatment extension…- benzinga.com Reported Saturday, Nektar's Rezpegaldesleukin Shows Statistically Significant EASI Improvements In 393-Patient Phase 2b REZOLVE-AD Trial And Proof-Of-Concept In Alopecia Areata At AAD 2026 Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patientsRezpegaldesleukin proof-of-concept data…
- benzinga.com Wedbush Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $70 Wedbush analyst Martin Fan initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $70.
- benzinga.com Nektar Therapeutics Announces New Data From Phase 2b Studies In Dermatitis And Alopecia Treatment Rezpegaldesleukin Has Been Accepted For Two Oral Presentations At The 2026 AAD Annual Meeting, March 27-31 Rezpegaldesleukin is a novel first-in-class regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory…
benzinga.com Earnings Scheduled For March 12, 2026 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Datadog, Spotify, Marriott, Ferrari And Other Big Stocks Moving Higher On Tuesday - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday - benzinga.com Earnings Scheduled For August 7, 2025
benzinga.com US Stock Futures Slip After Two Days Of Record Advances: 'FOMO Could Add Another 5%-10%…,' Says Expert U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower.